Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.49%||176.12||0.7%||$1154.91m|
|LLY||Eli Lilly & Co.||-0.17%||368.68||1.1%||$1075.50m|
|MRK||Merck & Co., Inc.||-0.98%||108.93||0.7%||$992.38m|
|BMY||Bristol-Myers Squibb Co.||-0.98%||79.91||1.1%||$741.36m|
|HZNP||Horizon Therapeutics Plc||-1.66%||96.85||5.4%||$295.13m|
|IDXX||IDEXX Laboratories, Inc.||-1.64%||415.39||3.9%||$191.92m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-2.90%||219.64||8.0%||$156.22m|
|NVO||Novo Nordisk A/S||-1.03%||125.77||0.1%||$154.68m|
Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.